Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions
Authors:
- Kathleen M. WestKWKathleen M. West
- Apol1 Stakeholders ProjectAPApol1 Stakeholders Project
Open Access
- 3 September 2019
- journal article
- research article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 50 (4) , 303-311
Abstract
Background: Apolipoprotein A1 (APOL1) gene variants occurring in people of West African descent contribute to the greater burden of kidney disease among African Americans. These variants are associated with increased risk of nondiabetic nephropathy, more rapid progression of chronic kidney disease, and shorter survival of donor kidneys after transplantation. However, only a minority of people with APOL1-associated risk develops kidney disease and specific clinical measures to address APOL1-associated risk are lacking. Given these uncertainties, we sought to engage members of the African American public in discussions with other stakeholders about the appropriate use of APOL1 testing. Methods: Formative interviews with community members, researchers, and clinicians in Seattle WA, Nashville TN, and Jackson MS, provided baseline information about views toward APOL1 testing and informed the design of 3 community-based deliberations among African Americans. A national meeting held in March 2018 included 13 community members, 7 scientific advisors and 26 additional researchers, clinicians, bioethicists, patient advocates, and representatives from professional organizations and federal funding agencies. Using small break-out and plenary discussion, the group agreed on recommendations based on current knowledge about APOL1-associated risk. Results: Meeting outcomes included recommendations to develop educational materials about APOL1 for community members and clinicians; to offer APOL1 research results to participants; and on the use of APOL1testing in kidney transplant programs. The group recommended against the routine offer of APOL1 testing in clinical care. Areas of disagreement included whether kidney transplant programs should require APOL1 testing of prospective living donors or bar individuals with APOL1 risk from donating kidneys and whether testing should be available on request in routine clinical care. Conclusion: We recommend continued discussion among stakeholders and concerted efforts to ensure active and informed participation of members of the affected community to guide research on APOL1 and kidney disease.Keywords
This publication has 22 references indexed in Scilit:
- APOL1-Associated Kidney Disease in BrazilKidney International Reports, 2019
- You Are Just Now Telling Us About This? African American Perspectives of Testing for Genetic Susceptibility to Kidney DiseaseJournal of the American Society of Nephrology, 2019
- Worldwide Frequencies of APOL1 Renal Risk VariantsNew England Journal of Medicine, 2018
- APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKDClinical Journal of the American Society of Nephrology, 2017
- Strict blood pressure control associates with decreased mortality risk by APOL1 genotypeKidney International, 2017
- APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American DonorsTransplantation, 2016
- APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South AfricansJournal of the American Society of Nephrology, 2015
- Testing for High-Risk APOL1 Alleles in Potential Living Kidney DonorsAmerican Journal of Kidney Diseases, 2015
- Should kidney donors be genotyped for APOL1 risk alleles?Kidney International, 2015
- Association of Trypanolytic ApoL1 Variants with Kidney Disease in African AmericansScience, 2010